The Purdue Institute for Cancer Research is one of only seven National Cancer Institute-Designated Basic Laboratory Cancer Centers in the nation. Since 1978, the institute’s top investigative minds have had one mission: basic, cancer-fighting discovery.

These discoveries are critical. Statistics show that one in three women and half of all men will be diagnosed with cancer in their lifetimes. Purdue discoveries already are helping prevent, detect, diagnose, treat and cure cancer. Brilliant Purdue researchers in engineering, veterinary medicine, nutrition, medicinal chemistry, pharmacy and biology, are all involved in the cancer institute’s persistent fight to conquer cancer.

**A LEADER CHANGING LIVES**

Purdue Institute for Cancer Research member Philip Low, the Ralph C. Corley Distinguished Professor of Chemistry, has created breakthrough therapeutic strategies that target only malignant cells and leave healthy cells alone.

Three of the agents he has developed were approved by the FDA within the last year:

- **CYTALUX™** – imaging technology that makes ovarian cancer easier to see and remove. CYTALUX™ targets only malignant cells and avoids healthy ones.
- **PLUVICTO™** – a targeted drug proven successful against a specific form of prostate cancer.
- **LOCAMETZ™** – an imaging agent that reveals prostate cancer cells. Use with PLUVICTO™ enables both targeting and treatment of prostate cancer.

Low also is investigating new approaches to reprogram the immune system to fix imbalances that contribute to nearly all major diseases, including cancers.
VITAL, LIFE-PRESERVING, URGENT WORK

Researchers at the Purdue Institute for Cancer Research are fighting bladder, pancreatic, prostate, lung, liver, ovarian, brain, colorectal, blood cancers, breast and cervical cancers as well as osteosarcoma. A recent $4.2 million grant from the Riney Foundation is supporting research for multiple myeloma.

The Purdue Institute for Cancer Research continues to tackle complex basic discovery, using engineering in oncology to develop therapeutics and invent new drug delivery systems. The institute also is using artificial intelligence and machine learning to break ground in personalized medicine and drug development. All this is happening while the cancer institute is training hundreds of future cancer scientists.

CANCER RESEARCH TO BENEFIT PET ANIMALS AND PEOPLE

With more than 70 million pet dogs in the U.S., cancer among pets is a growing challenge. Cancer institute researchers in the Purdue Comparative Oncology Program are seizing on the tremendous opportunity to simultaneously solve cancers that are similar in pets and humans. When a new successful approach to prevent, treat, or better manage cancer in pet animals is found, it often shows promise in humans.